Actively Recruiting
Prediction of Neoadjuvant Chemotherapy Response in Pancreatic Cancer
Led by City of Hope Medical Center · Updated on 2025-11-21
200
Participants Needed
1
Research Sites
82 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to develop and validate a predictive microRNA (miRNA) panel to assess the response to neoadjuvant chemotherapy (NACT) in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma (PDAC).
CONDITIONS
Official Title
Prediction of Neoadjuvant Chemotherapy Response in Pancreatic Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed pancreatic ductal adenocarcinoma (PDAC).
- Received neoadjuvant chemotherapy with FOLFIRINOX or gemcitabine plus nab-paclitaxel.
- Availability of pre-treatment plasma samples.
- Underwent curative-intent surgical resection (R0 or R1).
You will not qualify if you...
- Inadequate plasma samples or poor RNA quality for exosomal miRNA analysis.
- Non-adenocarcinoma histology.
- Presence of synchronous or multiple primary malignancies.
- Received chemotherapy regimens other than standard FOLFIRINOX or gemcitabine plus nab-paclitaxel.
- Presence of active inflammatory or autoimmune diseases.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
City of Hope Medical Center
Duarte, California, United States, 91016
Actively Recruiting
Research Team
A
Ajay Goel, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
6
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here